NCT04302025 2026-03-06
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
5 trialsNCT04589845 2026-03-06
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Recruiting
NCT04774718 2026-03-06
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06862869 2026-03-06
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Hoffmann-La Roche
Recruiting
NCT06765109 2026-02-17
ALKAZAR
Nuvalent Inc.
Phase 3 Recruiting